Very Interesting...21 Oct 2014 15:36
Scancell has a vaccine for skin cancer in clinical
trials. Early indications on animals are that when Scancell's vaccine is
used in combination with checkpoint inhibitors, the success rate for the
treatment rises from around 50% to around 85%. If this is borne out by
future trials, then Scancell's value may increase significantly.
Getmapping is making steady progress: sales and profits are on an upward
trend. Select has been growing and is now profitable and cash
generating. BioCote had accumulated a substantial cash reserve and
recently returned some capital to its shareholders.